## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (Currently amended): Peripheral blood mononuclear cells (PBMC) comprising one or more suppressor T cells capable of decreasing graft rejection of a solid organ by a recipient made by the process comprising:
  - a) isolating peripheral blood mononuclear cells (PBMC) from a recipient and an organ donor;
  - b) irradiating T cell-depleted mononuclear cells from said organ donor PBMC; and
  - c) combining ex vivo said recipient PBMC with said donor irradiated T cell-depleted mononuclear cells and a regulatory composition comprising TGF-β to induce one or more recipient suppressor T cells, wherein said suppressor T cells are CD4+CD25+ cells.
- 2. (Currently amended): A population of peripheral blood mononuclear cells (PBMC) comprising suppressor T cells capable of decreasing graft rejection of a solid organ by a recipient made by the process comprising:
  - a) isolating peripheral blood mononuclear cells (PBMC) from a recipient and an organ donor:
  - b) irradiating T cell-depleted mononuclear cells from said organ donor PBMC;
  - c) combining ex vivo said recipient PBMC with said donor irradiated T cell-depleted mononuclear cells and a regulatory composition comprising TGF-β to induce a PBMC population comprising one or more recipient suppressor T cells; and
  - d) wherein a recipient suppressor T cell population is produced by expanding said recipient suppressor T cells, and wherein said suppressor T cells are CD4+CD25+ cells.
- 3. (Previously presented): The PBMC comprising suppressor T cells according to Claim 1 or 2, wherein said regulatory composition further comprises cytokines selected from the group consisting of IL-2 and IL-15.

U.S. Patent Application No. 10/772,768 Attorney Docket No. 067797-5006-US01 (Formerly A-68983-2; 469443-00065)

- 4. (Currently amended): The PBMC comprising suppressor T cells according to Claim 1 or 2, wherein prior to step (b) said recipient PBMC are enriched for CD4+ T cells.
- 5. (Previously presented): The PBMC comprising suppressor T cells according to Claim 4, wherein said CD4+ cells are enriched for naïve CD4+ T cells.
- 6. (Cancel)